About VLX Ventures
VLX (Van Leer Xenia) Ventures was formed as a partnership between Xenia Venture Capital (TASE:XENA) and Van Leer Ventures, two leading Israeli early-stage investment centers, to jointly operate a technological incubator in Jerusalem and initiate and build-up innovative start-up companies in Israel.
Latest VLX Ventures News
Nov 7, 2020
... The development is based on an action observed in the immune system of insects that also deal with bacteria Omnix Medical, which is developing a drug against resistant bacteria, has completed a $ 10 million fundraiser since its inception. The current round of funding was led by investment funds Tal Capital (US) and Entrée Capital (IL) in partnership with CBG Group (UK) of British businessman Vincent Changwise Xenia Ventures (IL), VLX Ventures (IL) and supported by the Innovation Authority. The company has successfully completed animal experiments that have proven efficacy and safety in use, and the capital raised will allow the company to begin clinical trials in humans. The widespread use of antibiotics over the years has led to the creation of bacterial strains that have developed resistance to the vast majority of antibiotics currently in use, and the trend is continuing at an alarming rate. in the future, The effect of existing antibiotics will decrease significantly as the bacteria continue to improve and develop.. According to the World Health Organization, if humanity does not find new drugs against bacteria, we will reach an even more difficult situation than the current corona crisis. Experts warn that by 2050 more than 10 million people will lose their lives each year as a result of infection with resistant bacteria, More than mortality from cancer. Therefore, there is an immediate need to develop new strategies to fight resistant bacteria. Omnix Medical was founded in 2015 by Dr. Moshik Cohen-Kutner, Dr. Niv Bahnuf and Rom Lakritz. You The unique idea for the drug was developed by the entrepreneurs from an in-depth look at the activity of the immune system of insects against bacterial infections. Insects deal with disease-causing bacteria in their environment by way of “targeted elimination” – the explosion of the bacteria’s shell with the help of unique molecules that only harm bacteria and are not toxic to human cells. The company has recognized the tremendous potential inherent in these molecules and is developing patented technology based on their activity. Omnix began its journey in the VLX Ventures incubator, managed by Uri Choshen, which invested in it at the concept stage, together with the Innovation Authority, and helped the team build the company in the early stages of the venture. The in-depth research in the company’s laboratories and the experiments performed in accredited laboratories around the world, have shown that Omnix’s technology produces significantly more effective antibiotics compared to the drugs available on the market today. The company now plans to enter with its flagship drug, OMN6, into the phase of clinical trials in humans with the aim of fighting severe infections in hospitals that cause high mortality. Rom Lakritz, Moshik Cohen-Kutner, flattered. Photo by Omnix Press The market potential of the drug is huge: almost all the operations and processes in modern medicine available to us today depend on our ability to eliminate bacteria effectively with the help of antibiotics. Every year, over $ 45 billion in antibiotics are taken worldwide. Dr. Moshik Cohen-Kutner, CEO of Omnix: “The completion of the recruitment round enables the company to advance professionally and safely to the next stage in the development of the drug – the clinical trials, and to bring to the market a groundbreaking and life-saving technology.” Dr. Niv Bahnuf, Chief Scientist of Omnix: “We can say that we have adopted a natural technology that has proven to be extremely effective in killing bacteria for 200 million years. We have improved it with the unique engineering of Omnix in order to develop it as an innovative and life-saving antibiotic.” These were the details of the news Omnix Medical has completed $ 10 million in clinical trial of... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new. It is also worth noting that the original news has been published and is available at news1.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
VLX Ventures Investments
VLX Ventures has made 6 investments. Their latest investment was in Omnix Medical as part of their Seed VC on November 11, 2020.
VLX Ventures Investments Activity
VLX Ventures Team
4 Team Members
VLX Ventures has 4 team members, including current Chief Executive Officer, Ori Choshen.